Oncotelic presents four-gene liver cancer research

The retrospective HCC findings do not establish that the gene signature predicts benefit from everolimus, Sapu003, or other mTOR-directed therapies.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Oncotelic Therapeutics, Inc. representatives presented information about the PDAOAI platform and hepatocellular carcinoma research at Drug Discovery 2026 in Burlingame, California, on October 7 and 8, 2026. Product Manager Scott Myers described a workflow that searches and aggregates evidence across approximately 29 million PubMed abstracts, analyzing defined literature groups separately before combining findings.

Chief Business Officer Saran Saund presented a four-gene mTOR-related signature associated with overall survival in an exploratory discovery analysis and an independent Japanese patient cohort. The retrospective findings do not establish that the signature predicts treatment benefit from everolimus, Sapu003, or other mTOR-directed therapies. The presentations also described BIO REBOOT, which invites proposed therapeutic research projects; selected projects may qualify for startup funding and development support, subject to scientific review, available resources, and agreed terms.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

PubMed abstracts indexed: approximately 29 million abstracts Genes in mTOR-related signature: 4 genes

2 metrics

PubMed abstracts indexed approximately 29 million abstracts PDAOAI platform description

Genes in mTOR-related signature 4 genes Hepatocellular carcinoma research presentation

Key Terms

PDAOAI, Partitioned Literature Aggregation, hepatocellular carcinoma, mTOR-related signature

4 terms

PDAOAI technical

"PDAOAI platform"

Partitioned Literature Aggregation technical

"use of Partitioned Literature Aggregation"

hepatocellular carcinoma medical

"hepatocellular carcinoma (“HCC”) research"

Hepatocellular carcinoma is the most common form of primary liver cancer, arising from the main functional cells of the liver. For investors it matters because its serious health impact drives demand for diagnostic tests, treatments and long-term care; progress in trials or approvals can change a drugmaker’s revenue outlook much like a successful product launch can reshape a company’s future.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did OTLC present at Drug Discovery 2026?

Oncotelic Therapeutics presented information about its PDAOAI platform and hepatocellular carcinoma research. The platform’s search and evidence-aggregation workflow includes an index of approximately 29 million PubMed abstracts and analyzes defined literature groups separately before combining findings.

What does OTLC’s four-gene HCC signature show?

The signature, comprising FKBP1A, EIF4E, RRAGC, and PPARGC1A, was associated with overall survival in an exploratory discovery analysis and an independent Japanese patient cohort. The retrospective findings do not establish that it predicts treatment benefit from everolimus, Sapu003, or other mTOR-directed therapies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/13/2026 - 09:01 AM EDT Accepted by SEC EDGAR 10/13/2026 - 09:00 AM EDT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

October 7, 2026

ONCOTELIC THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware

000-21990

13-3679168

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

29397 Agoura Road, Suite 107

Agoura Hills, CA 91301

(Address of principal executive offices and Zip Code)

Registrant’s telephone number, including area code

(650) 635-7000

Not applicable.

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of class		Trading Symbols		Name of each exchange on which registered
N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On October 7 and 8, 2026, representatives of Oncotelic Therapeutics Inc. (the “Company”) presented information regarding its PDAOAI platform and hepatocellular carcinoma (“HCC”) research at Drug Discovery 2026 in Burlingame, California. The presentations, included as exhibits to this Current Report on Form 8-K, address the following:

- PDAOAI platform: Scott Myers, Product Manager, described the platform’s search and evidence-aggregation workflow, including its index of approximately 29 million PubMed abstracts and its use of Partitioned Literature Aggregation to analyze defined literature groups separately before combining findings.

- HCC research: Saran Saund, Chief Business Officer, presented a four-gene mTOR-related signature comprising FKBP1A, EIF4E, RRAGC, and PPARGC1A. The signature was associated with overall survival in an exploratory discovery analysis and an independent Japanese patient cohort. These retrospective findings do not establish that the signature predicts treatment benefit from everolimus, Sapu003, or other mTOR-directed therapies.

- BIO REBOOT: The presentations described an initiative inviting researchers and developers to propose therapeutic research projects using PDAOAI. Selected projects may qualify for startup funding and development support, subject to scientific review, available resources, and agreed terms.

Disclaimer.

The information in Section 8.01 of this Current Report on Form 8-K, including the information set forth in exhibits 99.1 and 99.2, are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Presentation 1
99.2		Presentation 2
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.